Remove Doctors Remove Genetics Remove Genomics
article thumbnail

UK agency pilots biobank to study links between genetics and drug side effects

Pharmaceutical Technology

The Medicines and Healthcare products Regulatory Agency (MHRA) aims to launch a pilot genetic biobank that will gather patient data to associate drug-related adverse events to their genetic makeup. The Yellow Card biobank will launch as a joint venture with the UK-government funded entity Genomics England on June 1.

article thumbnail

How Will Ultima Genomics and Genome Insight Make WGS Affordable?

XTalks

The application of whole genome sequencing (WGS) to derive a more complete understanding of cancer has been a central goal of cancer researchers even before the first human genome was decoded in 2003. Ultima Genomics has already partnered with other leading biotech startups.

Genome 97
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The use of genomic profiling testing to improve oncology care

pharmaphorum

Across LabCorp , we innovate through science and technology, with access to approximately 2,500 [doctors] and PhDs and over 700 patients. Everyone’s genetic makeup differs, and each person’s cancer experience is unique to them – how cancer develops, how fast it spreads, which drugs it responds to, and more. Tailored oncology.

Genomics 105
article thumbnail

UK-wide whole genome sequencing for newborns is feasible – but there are some key questions to answer first

pharmaphorum

Genomics England, the Department of Health and Social Care’s genome-sequencing hub, has this year announced that support for whole genome sequencing (WGS) has reached a level at which its national rollout on the NHS may someday become a reality. Only when genomic databases are diverse can we ensure that we all benefit equally.

Genomics 116
article thumbnail

Insights into Precision Dosing with Dr. Howard McLeod and Dr. Sharmeen Roy – Xtalks Life Science Podcast Ep. 163

XTalks

It leverages various patient-specific factors, including genetics, age, weight, organ function and even lifestyle, to determine the most appropriate dosage for each individual. Dr. Roy is passionate about leveraging technology to amplify the impact of the pharmacist.

article thumbnail

Building a better future for people with rare diseases in all four UK nations

pharmaphorum

Chaired by the Genetic Alliance, the virtual meeting saw representatives from Scotland, England, Wales, and Northern Ireland discuss the implementation of the UK Government’s Rare Disease Framework. We now know that 80% of rare diseases have a genetic origin. Genomic technology, therefore, has a key role to play in our work,” he said.

Genome 111
article thumbnail

Top 30 New Medical Devices of 2024

XTalks

A doctor inserts the catheter through a small incision in a vein in the groin and guides it to the heart. The catheters tip is positioned at various locations within the heart, where the doctor uses a generator to deliver RF energy. The genetic bleeding disorder is caused by the absence of blood clotting factor IX.